Related Experiment Video
Updated: Aug 5, 2026
06:24
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Menopausal Considerations in Transgender and Gender-Diverse Individuals
Neha Reddy1, Jill Liss2, Andrew R Fisher1
1Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA.
Obstetrics and Gynecology Clinics of North America
|July 27, 2026
Summary
Menopause management for transgender and gender diverse (TGD) individuals is emerging. Current medical guidelines are insufficient, necessitating reliance on data from cisgender populations and expert consensus for TGD care.
Area of Science:
- Endocrinology
- Gender-affirming care
- Menopause research
Background:
- Menopause assessment and treatment in transgender and gender diverse (TGD) individuals is a growing clinical concern.
- Limited research exists on cardiovascular, bone health, and neurocognitive outcomes in TGD individuals experiencing sex hormone loss.
- Existing literature is insufficient for evidence-based guidance on managing menopause in TGD populations.
Purpose of the Study:
- To review the current state of knowledge regarding menopause in transgender and gender diverse (TGD) individuals.
- To highlight the need for evidence-based guidelines for TGD menopause care.
- To inform clinical practice in gender-affirming care.
Main Methods:
- Literature review on menopause-related outcomes in TGD individuals.
- Analysis of current clinical practices and their limitations.
- Synthesis of existing data from cisgender populations and expert opinion.
Main Results:
- A significant gap exists in evidence-based guidelines for TGD menopause management.
- Clinical care currently relies on extrapolation from cisgender data, expert opinion, and shared decision-making.
- Further research is crucial to develop specific recommendations for TGD individuals.
Conclusions:
- There is a pressing need for more research into menopause in transgender and gender diverse (TGD) individuals.
- Current clinical management for TGD menopause is based on limited evidence and expert consensus.
- Developing specific, evidence-based guidelines is essential for improving care for TGD individuals experiencing menopause.
Related Concept Videos
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
01:40Hormonal Regulation
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...